Agilent 280-DS Mechanical Qualification System
The Agilent 280-DS Mechanical Qualification System (MQS) simplifies dissolution qualification. The system that has taken the dissolution industry by storm now has even more capabilities.
AGILENT 280-DS MQS CAPABILITIES EXTENDED
The Agilent 280-DS Mechanical Qualification System (MQS) redefines dissolution qualification. By making the physical parameter measurement simple and reliable, instrument integrity is vastly improved and failure investigations as a result of qualification failure are limited, if not entirely avoided. The accompanying software guides the user step-by-step through the qualification process and even trends instrument data to reveal potential problems before they become out-of-tolerance.
New! Compatible since its initial 2012 release with all Agilent, Varian, and VanKel models (as well as most open-head designed systems from various manufacturers), the 280-DS is now even more flexible. Minor modifications to the Vessel Module-including add-on spacers and an arm extension-have expanded the range of vessel heights where the 280-DS can be utilized.
All units currently being shipped contain these improvements, and existing units may be easily upgraded at the time of recalibration.
For more information on the 280-DS MQS, please contact your Agilent Representative, or email us at: dissolution.hotline@agilent.com.
Contact Details:
Company name: Agilent Technologies Inc. Website: www.agilent.com/lifesciences/280-DS
E-mail: dissolution.hotline@agilent.com.
Company Address
Agilent Technologies, Inc.
5301 Stevens Creek Blvd.
Santa Clara, CA 95051
United States
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
